Last reviewed · How we verify

Nature Cell Co. Ltd. — Portfolio Competitive Intelligence Brief

Nature Cell Co. Ltd. pipeline: 1 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 1 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Synvisc-One Synvisc-One marketed Viscosupplement; hyaluronic acid derivative Synovial fluid; joint cartilage surfaces Orthopedics; Rheumatology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Ain Shams Maternity Hospital · 1 shared drug class
  2. Gary A Levy, O. Ont. MD. FRCP AGAF · 1 shared drug class
  3. Gwo Xi Stem Cell Applied Technology Co., Ltd. · 1 shared drug class
  4. Manipal Acunova Ltd. · 1 shared drug class
  5. Mesoblast, Inc. · 1 shared drug class
  6. Tigenix S.A.U. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Nature Cell Co. Ltd.:

Cite this brief

Drug Landscape (2026). Nature Cell Co. Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/nature-cell-co-ltd. Accessed 2026-06-09.

Related